Month: June 2025

Introduction and Objective: Severe hypoglycemia (SH) poses a significant threat to persons with diabetes, with evidence of 30-40% of patients with type 1 diabetes (T1D) and 1-in-5 individuals with type 2 diabetes (T2D) experiencing severe events annually. Alarmingly, prescriptions for ready-to-use (RTU) glucagon remain drastically low: 22.4% of patients at increased risk currently receive RTU […]

Introduction and Objective: The incidence of type 2 diabetes (T2D) in younger adults is increasing, yet physical activity engagement in this population is underexplored. This study used co-design to develop a complex intervention to improve physical activity levels in people with young-onset T2D (18-40 years).Methods: Development involved three stages. Stage 1 extracted evidence from a […]

Introduction and Objective: The amount and rate of CO2 produced versus O2 consumed, called respiratory quotient (RQ), indicates the type and quantity of metabolic substrate utilized by the body and may be used as a marker of blood glucose estimation. We developed a hand-held device (Breath-AI V3) that measured end tidal breath CO2 along with […]

Introduction and Objective: Data indicate that the time of day at which exercise is performed may modulate glucose responses to resistance exercise, although limitations mean certainty of evidence is low. The objective of the current study, therefore, is to compare glucose responses to a bout of resistance exercise performed in the morning or in the […]

Introduction and Objective: The GRADE trial compared four glucose-lowering drugs for HbA1c reduction in individuals with type 2 diabetes mellitus (T2DM) on metformin monotherapy but lacked a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) arm. We emulated GRADE including SGLT-2i & excluding insulin.Methods: In a US commercial claims database (2014-2023), we used propensity score weighting to balance 87 […]

Introduction and Objective: Exercise increases hypoglycemia risk in people with T1D. Pre exercise whey protein ingestion, which stimulates glucagon secretion and endogenous glucose production, may be a novel strategy to mitigate hypoglycemia with exercise in T1D.Methods: Three adults with T1D (mean ± SD HbA1c 6.6 ± 0.3%) using MiniMed 780G underwent two bouts of moderate […]

Introduction and Objective: Gestational diabetes (GDM) increases risk of type 2 diabetes (T2D). We examined associations between nativity and glucose tolerance at 6-9 wks postpartum in women with recent GDM.Methods: 995 women with GDM and without T2D based on 2-h 75g oral glucose tolerance tests were classified with normoglycemia (fasting <100 and 2-h post-load <140 […]

Introduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent a paradigm shift in treating obesity. The substantial weight loss observed in clinical trials improves weight-related comorbidities. However, weight loss reported in the real world has been less than that seen in clinical trials. One hypothesis for this gap is that patients may not complete the […]

Introduction and Objective: Utreglutide (UTG, GL0034), a once weekly glucagon-like peptide-1 receptor agonist, demonstrated body weight (BW) reduction up to 3.3 kg after single dose and improvements in cardio-metabolic biomarkers after multiple ascending doses in obese subjects. This phase 1 trial assessed the safety and efficacy of UTG in overweight and obese subjects.Methods: The study […]

Introduction and Objective: Syndromic diabetes refers to the co-occurrence of diabetes with abnormalities of organ systems beyond the endocrine pancreas. RADIANT was established to study atypical forms of diabetes including syndromic diabetes. We aimed to characterize individuals with putative syndromic forms of diabetes in RADIANT.Methods: We defined syndromic diabetes based on 1 major and 1 […]